BDRX – biodexa pharmaceuticals plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Form 424B3 Biodexa Pharmaceuticals
Form 424B3 Biodexa Pharmaceuticals
Form EFFECT Biodexa Pharmaceuticals
Form EFFECT Biodexa Pharmaceuticals
Form POS AM Biodexa Pharmaceuticals
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.